Sequent Invest

Sequent Invest targets later-stage growth equity — companies that already generate recurring revenue and have proven unit economics. The firm writes cheques into commercial-stage businesses that require capital to expand geographically, build out sales teams, or acquire smaller competitors. It does not operate as a seed-stage or early-venture investor.

Sequent Invest makes direct investments into private companies, typically as a co-lead or sole institutional investor in a given round. There is no public record of the firm committing capital to third-party funds as a limited partner. The firm’s posture is that of a principal investor, not a fund-of-funds allocator.

Publicly available information does not allow a confirmed sector-exclusion list. Based on the firm’s growth-equity posture and Nordic technology focus, it is unlikely to invest in natural resources extraction, real estate development, or heavily regulated financial services where the operator must hold a banking license. The absence of any disclosed biotechnology or medical-device investments suggests healthcare exposure is minimal.

Sequent Invest does not publicly name its managing partners, investment committee members, or senior deal leads. No principals are listed on the firm’s website or on LinkedIn. The governance structure — whether a single decision-maker, a consensus committee, or an external capital beneficiary with final approval — is not a matter of public record.

Sourcing is likely relationship-driven, relying on the network the principals have built within the Stockholm-DACH-London technology corridor. Without a public brand, the firm competes for deals on the strength of individual track records and the ability to commit quickly without fund-level disclosure requirements that slow larger institutional peers. No external business-development function or intermediary-outreach program is visible.